Glaukos Corporation (NYSE: GKOS) and HeartWare International (NASDAQ:HTWR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitabiliy, dividends and earnings.

Volatility & Risk

Glaukos Corporation has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, HeartWare International has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Glaukos Corporation and HeartWare International, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Glaukos Corporation 0 0 7 0 3.00
HeartWare International 0 6 1 0 2.14

Glaukos Corporation presently has a consensus target price of $49.20, indicating a potential upside of 19.50%. HeartWare International has a consensus target price of $58.00, indicating a potential upside of 0.03%. Given Glaukos Corporation’s stronger consensus rating and higher possible upside, analysts clearly believe Glaukos Corporation is more favorable than HeartWare International.

Valuation and Earnings

This table compares Glaukos Corporation and HeartWare International’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Glaukos Corporation $127.21 million 11.10 $8.53 million $0.11 374.31
HeartWare International N/A N/A N/A ($3.40) -17.05

Glaukos Corporation has higher revenue and earnings than HeartWare International. HeartWare International is trading at a lower price-to-earnings ratio than Glaukos Corporation, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

89.0% of Glaukos Corporation shares are owned by institutional investors. 16.4% of Glaukos Corporation shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


This table compares Glaukos Corporation and HeartWare International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Glaukos Corporation 3.54% 3.95% 3.43%
HeartWare International -15.84% -25.32% -10.14%


Glaukos Corporation beats HeartWare International on 11 of the 11 factors compared between the two stocks.

Glaukos Corporation Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.

HeartWare International Company Profile

Heartware International, Inc. is a medical device company. The Company develops and manufactures miniaturized implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure. The Company operates in the segment of design and manufacture of medical devices. The HeartWare Ventricular Assist System (HVAD System), which includes a ventricular assist device (VAD) or blood pump, patient accessories and surgical tools, provides circulatory support for patients in the advanced stage of heart failure. The HVAD System is designed to be implanted adjacent to the heart, avoiding abdominal surgery. The HVAD System features the centrifugal pump designed to be implanted in the chest, directly adjacent to the heart. It develops MVAD System, a miniaturized device. The CircuLite Surgical System is designed to be implanted through a right, mini-thoracotomy procedure and does not require a sternotomy or cardiopulmonary bypass.

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with's FREE daily email newsletter.